Abstract
The field of antiretroviral therapy has witnessed remarkable progress during the past 15 years. There are now over a dozen approved therapeutic agents for infection with the human immunodeficiency virus (HIV), a pathogen that once caused nearly uniformly fatal illness. These agents usually target two essential enzymes of the virus, the reverse transcriptase and the protease. The era of potent antiretroviral therapy, also termed highly active antiretroviral therapy, began in 1996 and has been marked by dramatic declines in morbidity and mortality due to HIV disease in the developed world. These advances have not been without their cost in terms of drug resistance and toxicity and unwanted effects. Concern about these negative effects has led to a more conservative approach to the timing of the initiation of therapy and to clinical trials of intermittent therapy in an attempt to decrease the total exposure to drugs over time. Immune-based approaches such as therapeutic vaccination may someday permit viremia to be controlled in the absence of drugs. Antiviral potency has been the key to the initial success of drug regimens, as well as to the durability of their success, the restoration of immune function, the prevention of the emergence of resistance, and ultimately the prevention of disease progression. Future progress in antiretroviral therapy will bring more choices for physicians and patients and will make an already complex field both more challenging and more rewarding.
Keywords: hiv, antitretroviral therapy, combination therapy, toxicity, haart
Current Topics in Medicinal Chemistry
Title: Current Treatment of HIV Infection
Volume: 3 Issue: 13
Author(s): Simon Portsmouth, Justin Stebbing and Brian Gazzard
Affiliation:
Keywords: hiv, antitretroviral therapy, combination therapy, toxicity, haart
Abstract: The field of antiretroviral therapy has witnessed remarkable progress during the past 15 years. There are now over a dozen approved therapeutic agents for infection with the human immunodeficiency virus (HIV), a pathogen that once caused nearly uniformly fatal illness. These agents usually target two essential enzymes of the virus, the reverse transcriptase and the protease. The era of potent antiretroviral therapy, also termed highly active antiretroviral therapy, began in 1996 and has been marked by dramatic declines in morbidity and mortality due to HIV disease in the developed world. These advances have not been without their cost in terms of drug resistance and toxicity and unwanted effects. Concern about these negative effects has led to a more conservative approach to the timing of the initiation of therapy and to clinical trials of intermittent therapy in an attempt to decrease the total exposure to drugs over time. Immune-based approaches such as therapeutic vaccination may someday permit viremia to be controlled in the absence of drugs. Antiviral potency has been the key to the initial success of drug regimens, as well as to the durability of their success, the restoration of immune function, the prevention of the emergence of resistance, and ultimately the prevention of disease progression. Future progress in antiretroviral therapy will bring more choices for physicians and patients and will make an already complex field both more challenging and more rewarding.
Export Options
About this article
Cite this article as:
Portsmouth Simon, Stebbing Justin and Gazzard Brian, Current Treatment of HIV Infection, Current Topics in Medicinal Chemistry 2003; 3 (13) . https://dx.doi.org/10.2174/1568026033451808
DOI https://dx.doi.org/10.2174/1568026033451808 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Characterization and Antihypertensive Effect of the Complex of (-)-β- pinene in β-cyclodextrin
Current Pharmaceutical Biotechnology The Role of Protease-Activated Receptors for the Development of Myocarditis: Possible Therapeutic Implications
Current Pharmaceutical Design Inhibition of Smooth Muscle Cell Migration and Proliferation by Statins
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Novel Approaches to the Therapy of Rheumatoid Arthritis based on an Understanding of Disease Mechanisms
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Clinical Utility of Biomarkers in Premature Atherosclerosis
Current Medicinal Chemistry New Molecular Targets of Anticancer Therapy – Current Status and Perspectives
Current Medicinal Chemistry Pharmacotherapy of Dilated Cardiomyopathy
Current Pharmaceutical Design Therapeutic AIDS Vaccines
Current Pharmaceutical Design Studies on Novel Pyridine and 2-pyridone Derivatives of N-arylpiperazine as α-adrenoceptor Ligands
Medicinal Chemistry Mechanisms of Incretin Effects on Plasma Lipids and Implications for the Cardiovascular System
Cardiovascular & Hematological Agents in Medicinal Chemistry Treatment of HCV-Related Mixed Cryoglobulinemia
Current Drug Targets Review of the Biological Activity of Maslinic Acid
Current Drug Targets Respiratory Tract Manifestations of Rheumatic Diseases in Children
Current Respiratory Medicine Reviews Refractory Behçet’s Disease with Multi-organ Involvement - Learning from Failure
Current Rheumatology Reviews Pleural Involvement in Systemic Disorders
Current Drug Targets - Inflammation & Allergy Therapeutic Angiogenesis: Recent and Future Prospects of Gene Therapy in Peripheral Artery Disease
Current Gene Therapy New Approaches in the Management of Septic Shock
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Established Treatments of Psoriasis
Current Drug Targets - Inflammation & Allergy Heart Failure in Sub-Saharan Africa
Current Cardiology Reviews Reactive Oxygen Species in Pathogenesis of Atherosclerosis
Current Pharmaceutical Design